Establishment Labs Holdings Inc. (NASDAQ:ESTA) Stock Has Consensus Target Price of $100.25 According to Brokerages

Establishment Labs Holdings Inc. (NASDAQ:ESTA) has been assigned an average rating of “Moderate Buy” from the nine analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $100.25.

A number of equities analysts have commented on the stock. Canaccord Genuity Group set a $105.00 price objective on shares of Establishment Labs in a research report on Thursday, August 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a report on Monday. Citigroup upgraded shares of Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price objective for the company in a research report on Thursday, August 13th. JPMorgan Chase & Co. lifted their price objective on Establishment Labs from $84.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Finally, Mizuho boosted their target price on Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th.

Hedge Funds Weigh In On Establishment Labs

Several hedge funds have recently bought and sold shares of the company. Integrated Wealth Concepts LLC acquired a new position in shares of Establishment Labs in the second quarter worth $32,000. KBC Group NV acquired a new position in Establishment Labs in the 1st quarter valued at $28,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Establishment Labs during the 2nd quarter worth $43,000. State of Wyoming acquired a new stake in shares of Establishment Labs during the second quarter worth $87,000. Finally, MV Capital Management Inc. purchased a new stake in shares of Establishment Labs in the fourth quarter valued at $146,000. 72.91% of the stock is owned by hedge funds and other institutional investors.

Establishment Labs Stock Up 0.6%

Shares of NASDAQ:ESTA opened at $65.97 on Monday. The company has a quick ratio of 2.52, a current ratio of 3.84 and a debt-to-equity ratio of 12.11. The firm’s 50 day moving average price is $77.83 and its 200 day moving average price is $74.41. The stock has a market cap of $1.97 billion, a price-to-earnings ratio of -50.36 and a beta of 1.05. Establishment Labs has a fifty-two week low of $37.37 and a fifty-two week high of $97.59.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). The firm had revenue of $67.54 million during the quarter, compared to analysts’ expectations of $65.79 million. Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. Establishment Labs’s quarterly revenue was up 31.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.57) EPS. As a group, equities research analysts predict that Establishment Labs will post -1.15 earnings per share for the current fiscal year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a medical technology company focused on developing, manufacturing and commercializing products for breast aesthetics and reconstruction. Founded in 2004 and headquartered in Alajuela, Costa Rica, the company serves plastic surgeons, healthcare providers and patients in markets around the world.

Its portfolio is centered on the Motiva line of breast implants, including implants designed for cosmetic augmentation and reconstructive procedures. Establishment Labs also develops related technologies and products, including tissue expanders and surgical systems, as well as Mia Femtech, a minimally invasive breast-enhancement procedure and platform.

The company operates internationally through direct sales and distribution partnerships.